Previous 10 | Next 10 |
- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technology for targeting hematologic and solid tumor cancers NEW YORK, April 09, 2024 (GLOB...
2024-03-14 17:54:40 ET More on IN8bio In8bio stock jumps 11% following clinical update Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio Read the full article on Seeking Alpha Fo...
Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission, including six Patients Alive and Progression Free Past 12 Months Presented Positive Results ...
New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented. The platform has demonstrated the ability to target cancer cells while sparing healthy tissue when both express the...
IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the following investor conferences in March: TD Cowen 44 th Annual Health Care Conf...
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach...
2024-01-12 17:20:34 ET More on IN8bio In8bio stock jumps 11% following clinical update For further details see: IN8bio files to sell 42.7M shares for holders
2024-01-04 15:26:32 ET More on IN8bio Seeking Alpha’s Quant Rating on IN8bio Historical earnings data for IN8bio Financial information for IN8bio For further details see: In8bio stock jumps 11% following clinical update
Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored trial of INB-100 at the 65 th American Society of Hematology (ASH) Annual Meeting & Exposition Presented new data ...
2023-12-15 08:38:22 ET Losers: Aadi Bioscience AADI -54% on study data for anti-tumor drug . Inno Holdings ( INHD ) -45% . Eos Energy Enterprises EOSE -23% announces launch of proposed $40M public offering . Chavant Capital Acquisition Corp ( CLAY...
News, Short Squeeze, Breakout and More Instantly...
IN8bio Inc. Company Name:
INAB Stock Symbol:
NASDAQ Market:
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB) a clinical-stage biopharmaceutical company developing innovative gamma-del...
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28 th ...
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB) a clinical-stage biopharmaceutical company developing innovative gamma-del...